The stock market remains bullish over cannabis, despite an end of the recent break-out rally. I recommend an investment strategy with firm positions in cannabis stocks and support stocks. There should be long holds and some short-term strategies. The current rally shows continued promise because of the ongoing discussions about federal legalization and cannabis banking reform.
One should invest in a variety of cannabis stocks, including CBD/hemp retail stocks, medical cannabis research, and retail cannabis. In addition, one ought to consider cannabis support stocks, like grow equipment, real estate, computer integration, and nutrient sales. A prudent investor should also consider American OTC (Over-the-Counter) cannabis stocks as well, in order to have a full net over the industry.
India Globalization Capital is thriving in the cannabis industry
India Globalization Capital (NYSE:IGC) is a conglomerate which has revenue streams from the Industrial Sector (Heavy Construction) and the Health Care Sector (Specialty Products). They are recently conducting business in the cannabis and CBD industries and have a promising outlook. The company already has an established hemp grow and CBD product distribution network in the American market. Their phase 1 clinical studies in medical cannabis are already underway.
They run an infrastructure business in India where they conduct general contracting, resale of physical commodities, and the rental of heavy construction equipment. This business also has outlets in Hong Kong and Colombia. They hold their headquarters in Maryland and have a facility in Washington. In their US business, they sell full spectrum CBD products and conduct psychoactive cannabinoid medical research.
India Globalization Capital is interested in health curatives which use cannabinoids with a view to treating Alzheimer’s, Parkinson’s, Epilepsy, and chronic pain. They undergo research and development, clinical stage trials, and ensure medical patents. They are currently conducting a 12 subject phase 1 human clinical trial for the treatment of Dementia in
